|
Strychnos nux-vomica
|
B01.650.940.800.575.912.250.456.875.750.500 |
|
|
Hemorrhagic Septicemia
|
C01.150.252.100.375 |
|
|
Bacteremia
|
C01.150.252.100 |
|
|
Warm-Up Exercise
|
G11.427.410.698.277.968 |
|
|
Uterine Balloon Tamponade
|
E02.520.392.500.500 |
|
|
Balloon Occlusion
|
E02.520.392.500 |
|
|
Coronavirus OC43, Human
|
B04.820.578.500.540.150.113.500.500 |
|
|
Immune Tolerance
|
G12.535.425 |
|
|
DNA Fragmentation
|
G05.200.230 |
|
|
Glia Maturation Factor
|
D12.644.276.860.325 |
|
|
Escherichia coli K12
|
B03.440.450.425.325.300.360 |
|
|
Pineal Gland
|
A08.713.733 |
|
|
Trimethaphan
|
D03.383.129.308.935 |
|
|
Picolinic Acids
|
D03.066.707 |
|
|
Fenofibrate
|
D02.522.223.750 |
|
|
Practice Patterns, Pharmacists'
|
D000086702 |
[Patterns of practice related to how PHARMACISTS prepare or compound PRESCRIPTION DRUGS as especially influenced by cost of the service requested and provided.
] |
|
Chromatids
|
G05.360.160.175 |
|
|
Dual Specificity Phosphatase 3
|
D12.776.476.445.300 |
|
|
Sickness Impact Profile
|
N05.715.360.300.800.438.375.730 |
|
|
Glymphatic System
|
A07.521 |
|
